The greater potency of ciprofloxacin in vitro to that of ofloxacin against Pseudomonas aeruginosa may be potentially offset by the more favorable pharmacokinetic profile of the latter drug. In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vivo for ciprofloxacin at a peak concentration (CT A 3 log.o kill (T3 kill) of P. aeruginosa ATCC 27853 was achieved in 0.15 h by ciprofloxacin and of P. aeruginosa PSA 9258 in 0.09 h. Ofloxacin at a CP^ of 8 mg/L and T m of 6 h achieved a T3 kill off. aeruginosa ATCC 27853 in 0.74 h and of P. aeruginosa PSA 9258 in 0.16 h. The area under the kill curve (AUKC) was 1.10 x 10*and 1.96 x ^mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CP^ 8 mg/L and a T ia of 6 h was 9.78 x 10*and 2.20 x WmL-h/cfu respectively. Significant differences (P > 0.05) were evident between ciprofloxacin and all ofloxacin regimens against P. aeruginosa ATCC 27853 but not against P. aeruginosa PSA 9258.
Introduction
The minimum inhibitory concentrations (MIC) of new antimicrobial agents is frequently employed to estimate their relative potency. However, MIC determinations do not incorporate the pharmacokinetic properties of individual antimicrobial agents.
Thus, although the activity of ciprofloxacin against Pseudomonas aeruginosa is generally two to eight times greater than that of ofloxacin with typical MIG»s for P. aeruginosa being 0.25 mg/L of ciprofloxacin and 2.0 mg/L of ofloxacin, the pharmacokinetic profile of ofloxacin is more favorable than that of ciprofloxacin (Wolfson & Hooper, 1989) . While protein binding of both agents is approximately 30%, ofloxacin has a longer T\n of 5-8 h compared with 3-5 h for ciprofloxacin (Wolfson & Hooper, 1989; Lamp, Bailey & Rybak, 1992) . At the doses of ofloxacin used clinically, a steady state CP,^ of 3.3-8.1 mg/L is achieved whereas the corresponding CP^** for ciprofloxacin is 3.3-4.2 mg/L (Soledad, 1989; Vance-Bryan, Guay & Rotschafer, 1990; Todd, 1991; Lamp et al., 1992; Just, 1993) . The longer elimination T xa and higher CP result in an AUC that is up to five times that of ciprofloxacin (Wolfson & Hooper, 1989) . Therefore, at least in theory, the differences in MICs between ciprofloxacin and ofloxacin could be compensated for by the increased AUC. The purpose of this study was to compare the antibacterial activity of ciprofloxacin and ofloxacin using time concentration kill curves against two different strains of P. aeruginosa by simulating the actual in-vivo pharmacokinetic parameters of the respective agents in an in-vitro pharmacodynamic model.
Materials and methods
The antimicrobial activity of ofloxacin and ciprofloxacin was determined by simulating the following CP^ and monoexponential T l/2 to reflect those achieved in clinical practice: (1) direct comparisons of ofloxacin and ciprofloxacin utilising identical CT' mu of 5.0 mg/L 7*1/ 2 of 4.5 h, (2) direct comparisons of ofloxacin and ciprofloxacin utilising the same CP nai (5.0 mg/L) but increasing the ofloxacin T in to 6.0 h while maintaining the ciprofloxacin T ](2 at 4.5 h, and (3) comparison of C/W and T m of ofloxacin of 8.0 mg/L and 6.0 h respectively and of ciprofloxacin of 5.0 mg/L and 4.5 h.
Determination of the MIC
P. aeruginosa ATCC 27853 and a clinical isolate, P. aeruginosa PSA 9258 were subcultured for three consecutive days before determining the MIC in triplicate using an inoculum of 10 5 cfu/mL in a commercial colourimetric microdilution panel (Alamar, Sacramento, CA, USA).
Preparation of ofloxacin and ciprofloxacin
Stock solutions of 3.6 g/L analytical grade ofloxacin (Lot N-7216 R.W. Johnson, Raritan, NJ, USA) and 3 g/L ciprofloxacin (Lot 9110086, Miles, West Haven, CT, USA were prepared, distributed in aliquots and frozen at -70°C. When required for use, an aliquot of drug was thawed and the appropriate quantity necessary for the experiments was measured.
In-vitro pharmacodynamic model
The in-vitro pharmacodynamic model used in these experiments was identical to that described by Zabinski et al. (19936) except that the experiments were conducted aerobically. Briefly, the model consisted of a 750 mL glass vessel with inflow and outflow ports, connective silicon tubing (Masterflex L/S thin wall tubing; Cole-Parmer, Chicago, IL, USA), a Masterflex peristaltic pump (Cole-Parmer) and reservoirs for fresh and waste media. The peristaltic pump propelled antibiotic free media into the glass vessel displacing an equal volume of media containing antibiotic resulting in progressive dilution to yield a monoexponential pharmacokinetic process.
All experiments were performed in duplicate and involved a single bolus injection of antibiotic. Experiments were conducted for 24 h in Mueller-Hinton broth which contained 720mg/L Ca +2 and 610mg/L Mg +2 (CAMHB). Before beginning the time concentration kill curve experiments each P. aeruginosa was subcultured twice in CAMHB to allow the organisms to achieve exponential growth. In addition, growth control experiments were performed for each strain employing a flow rate that simulated a T\p. of approximately 4.5 h using an initial inoculum of approximately 10 6 cfu/mL. Samples of 1 mL were removed from the model immediately after adding the fluoroquinolone and 5, 15, 30 and 45 min later then again 1, 2, 3, 4, 6, 10, 13, 20 and 24 h after adding the drug. These samples were used to estimate viable counts by performing a series of decimal dilutions of 100 /ih media in cold saline and inoculating each dilution onto trypticase soy agar supplemented with 5% sheep blood (Dimed, New Brighton, MN, USA). Carryover of drug was prevented by exposing each undiluted sample to polymeric binding resin (Rohn and Haas, Philadelphia, PA, USA; Zabinski et al., 1993a) . The lower limit of detection for bacterial counts was estimated to be 2.3 x lO'cfu/mL.
Determination of the pharmacokinetic parameters
Samples collected at 1.6, and 13 h after introducing the drugs were frozen at -70°C and later quantitatively analysed for ofloxacin or ciprofloxacin using HPLC (Herman et al., 1991) . CP^ concentrations and T ip were calculated using standard equations for monoexponential pharmacokinetics (Sawchuk et al., 1977) . The AUC was calculated using the trapezoidal method of Rowland & Tozer (1989) and the AUIC was calculated by the method described by Schentag, Nix & Adelman (1991) .
Time kill curve data were expressed as mean values for the duplicate kill curves of the time taken to achieve a 3 logio kill (T3 kill), the kill rate constants (K,), and the area under the kill curve (AUKC) which was calculated by the log trapezoidal method of Yeh and Kwan (1978) . Regrowth and viable counts that were below the limit of detection were not included in AUKC calculations. In experiments in which bacterial counts dropped below 2.3 x 10 2 cfu/mL, the linear regression equation for bacterial kill was extrapolated to determine the time at which bacterial counts fell below the limit of counting detection. This was then used to determine the area beyond the last bacterial sampling point before counts fell below the limit of detection. In kill curves in which bacterial counts remained above the limit of detection, area calculations were based on the time at which the lowest bacterial count occurred.
Statistical analysis
One way ANOVA (SPSS, Chicago, IL, USA) was used to determine the significance of any differences between drugs. Differences between individual treatment regimens were determined utilising Duncan's range test (P < 0.05) (Duncan, 1955) . Regression analyses of kill and regrowth data, AUC, AUIC, and AUKC were performed using Statview™ (Cricket Software, Philadelphia, PA, USA). For the purposes of analysis, AUKC data were standardized by dividing AUKC by the cfu/mL obtained at time zero.
Results
The MICs of ciprofloxacin for P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258 were both 0.25 mg/L and of ofloxacin were 2.0 and 1.0 mg/L, respectively.
The concentrations of ofloxacin and ciprofloxacin in media samples collected during experiments indicated good correlation with the desired CPu^ and elimination T ]n . The most favourable pharmacokinetic profile of ofloxacin resulted in twice the AUC as that of the ciprofloxacin dosing regimen (Table) , but, regardless of how the ofloxacin serum concentration time curve was constructed, the AUIC values of ciprofloxacin remained at least double those of ofloxacin (Table) .
In all experiments, the T3 kill was significantly less, and the K K significantly greater, for ciprofloxacin than for ofloxacin against P. aeruginosa ATCC 27853 (Table) . In addition, the magnitude of bacterial kill, exemplified by the AUKC, was greater for ciprofloxacin than for ofloxacin against this isolate for all dosing regimens. The rate and magnitude of kill against P. aeruginosa ATCC 27853 increased for ofloxacin as the AUC increased; however, only the least fa\curable pharmacokinetic regimen i.e. CP5
.0 mg/L and T m 4.5 h and the most favourable pharmacokinetic regimen i.e. CP^ of 8.0 mg/L and T in of 6.0 h were significantly different. The time concentration kill curves for ofloxacin and ciprofloxacin against P. aeruginosa ATCC 27853 are depicted in Figure 1 .
Against the clinical isolate P. aeruginosa PSA 9258, the differences in rate and magnitude of bacterial kill between ofloxacin and ciprofloxacin were much less pronounced. Comparison of T3 kill and K R for this strain showed that the T3 kill for this strain was significantly less, and the K R significantly greater, for all dosage regimens except for the most favourable ofloxacin pharmacokinetic regimen i.e. CP^, of 8.0 mg/L and T V2 of 6.0 h. The rate of kill was significantly greater for ciprofloxacin. However, the magnitude of kill was not significantly different when ciprofloxacin was compared against a C^ of ofloxacin of 8.0 mg/L and T m of 6.0 h. Both the rate and magnitude of bacterial kill increased with an increasing AUC of ofloxacin but the differences were not all statistically significant. The time concentration kill curves profiles for ofloxacin and ciprofloxacin against P. aeruginosa PSA 9258 are depicted in Figure 2 .
The relationship between the specific AUKC calculated from the kill portion of the curves and the AUC of ofloxacin was linear for both P. aeruginosa ATCC 27853 (r = 0.94) and P. aeruginosa PSA 9258 (r = 0.83). Pooling the AUCs of ciprofloxacin and ofloxacin lowered the correlation between the AUKC and AUC to 0.22 and 0.10 for P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively. Regression of AUKC and AUIC for both ciprofloxacin and ofloxacin data resulted in correlation coefficients of 0.96 and 0.93 for P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively. The pooled regression analysis of the AUKC and the AUC or AUIC resulted in correlation coefficients of 0.04 and 0.80, respectively. 
Discussion
Ciprofloxacin exhibited a faster rate and larger extent of bacterial kill against both strains of P. aeruginosa than did ofloxacin. However, the significant difference in the magnitude of bacterial kill was negated by utilising a typical AUC of ofloxacin against the more susceptible P. aeruginosa, but not against the more resistant strain. Each strain was exposed to only a single dose of drug for a limited duration and the efficiency of ciprofloxacin in killing P. aeruginosa would seem to favour this drug. However, this might not be translated into clinical practice as treatment with ofloxacin or ciprofloxacin does not appear to result in a significant difference in the outcome. The pharmacodynamic parameter AUIC is particularly attractive for comparing antimicrobial agents with different pharmacokinetic and susceptibility profiles as it is equivalent to the area under the serum concentration time curve divided by the bacterial MIC. Several investigators have suggested that the AUIC might be used to measure fluoroquinolone potency (Nightingale, 1993; Schentag, et al., 1991; Forrest et al., 1993) . Despite the superior pharmacokinetic profile of ofloxacin, have postulated that ciprofloxacin should outperform ofloxacin in treating infections due to P. aeruginosa due to a higher achievable AUIC. However, there have been no reports of a direct comparison between fluoroquinolones utilising the AUIC as an outcome measurement.
The MIC of ofloxacin for P. aeruginosa PSA 9258 was 1.0 mg/L and therefore the AUC and AUIC were the same whereas those of ciprofloxacin were not since the MIC was 0.25 mg/L. In contrast, the AUC differed from the AUIC of both drugs for P. aeruginosa ATCC 27853 since the MIC of ofloxacin was 2.0 mg/L and that of ciprofloxacin was 0.25 mg/L, resulting in values that were less than unity. The differences in MICs between the two strains were therefore important since, despite the almost identical AUCs and AUICs for P. aeruginosa PSA 9258, and the completely different values for P. aeruginosa ATCC 27853, a poor correlation was seen for the pooled AUC whereas the correlation was stronger for the AUIC.
In conclusion, the kill curves generated in vitro indicate that the more favorable pharmacokinetic profile of ofloxacin may not fully compensate for the decreased susceptibility of ofloxacin against P. aeruginosa at clinically achievable concentrations. These results also suggest that different fluoroquinolones can be compared using a hybrid parameter such as the AUIC that incorporates the pharmacokinetics and antimicrobial susceptibility against specific bacterial isolates.
